spacer
home > epc > summer 2002 > financing within the smo industry
PUBLICATIONS
European Pharmaceutical Contractor

Financing Within the SMO Industry

In the early 1990s a new phenomenon in the conduction of clinical trials began to emerge. Up until then physicians conducted clinical trials within their own practices. GPs and specialists recruited trial patients from their own databases. However, Good Clinical Practice (GCP) guidelines subsequently became more stringent and physicians involved in day-to-day health care became increasingly reluctant to concentrate on clinical trials.

The concept evolved of an organisation dedicated to conducting clinical trials with specialist physicians and nurses. The organisations were initially called trial management organisations and later became known as site management organisations (SMOs).

They were company-owned sites which had the best control over the specific trial circumstances. Because of this, an SMO had to cover a number of fixed costs such as physicians' and nurses' salaries. As SMOs have to at very least cover their costs in order to stay in business, I have tried to summarise the cost factors and income in this article. This summary is based on a practical evaluation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Henk Mulder of Osteosupport

Dr Henk Mulder achieved his PhD in Internal Medicine and Endocrinology. He wrote his thesis 'Calcitonine concentration in blood in several disease sates' in 1980 at the University of Amsterdam.

After two decades of working as an Internist/Endocrinologist for the university hospital in Leiden and at a local hospital in Rotterdam, he founded the first European site management organisation named Good Clinical Practice (GCP). He participated in over 100 clinical trials as a Principal Investigator.

In early 2001 he left GCP and in June 2001 he founded Osteosupport - a hybrid company with integrated medical, paramedical and clinical trial activities. Osteosupport has been successfully involved in conducting three studies in the areas of arthritis, hypertension and male hormone replacement therapy.

spacer
Dr Henk Mulder
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The need for a blueprint emergency plan to avoid a HPAPI crisis

SMi reports: Taro Pharmaceuticals, Purdue Pharma and Sakari Consultants to present at HPAPI USA taking place on October 21st – 22nd in Boston
More info >>

White Papers

Backward Thinking

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement